Search results for "LIVER DISEASE"

showing 10 items of 913 documents

Disposition of azapropazone in chronic renal and hepatic failure.

1981

The disposition of azapropazone 600 mg i.v. was investigated in 6 healthy subjects, 13 patients with cirrhosis and 8 patients with renal failure. In healthy subjects the elimination half-life was 12.2±2.1 h (mean ± SD), the volume of distribution 10.6±3.31 and the total clearance was 597±135 ml·h−1. Renal clearance accounted for about 62% of the total clearance. The free fraction of azapropazone in the plasma was 0.0045±0.0006. The patients with cirrhosis were divided into Group I with modest and Group II with severe impairment of liver function. In Group I the total clearance of azapropazone was not significantly different from that in healthy subjects. There was a 2.5-fold increase in its…

AdultApazoneMalemedicine.medical_specialtyCirrhosisUrologyRenal functionchemistry.chemical_compoundPharmacokineticsInternal medicineMedicineHumansPharmacology (medical)AzapropazonePharmacologyVolume of distributionCreatininebusiness.industryTriazinesLiver DiseasesGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologychemistryFree fractionCreatinineKidney Failure ChronicLiver functionbusinessmedicine.drugHalf-LifeEuropean journal of clinical pharmacology
researchProduct

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2…

2019

Norursodeoxycholic acid is an orally administered side chain-shortened homologue of ursodeoxycholic acid that undergoes hepatic enrichment with hepatoprotective, anti-inflammatory, and antifibrotic activity. We assessed the efficacy of two doses of norursodeoxycholic acid versus placebo for the treatment of non-alcoholic fatty liver disease.We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 dose-finding clinical trial in tertiary referral hospitals and medical centres in Austria (n=6) and Germany (n=23) for patients with non-alcoholic fatty liver disease with or without diabetes. Patients with a clinical diagnosis of non-alcoholic fatty liver disease and serum alani…

AdultBlood GlucoseMalemedicine.medical_specialtyCholagogues and CholereticsPopulationPlaceboGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumansAspartate Aminotransferaseseducationeducation.field_of_studyHepatologyDose-Response Relationship Drugbusiness.industryFatty liverUrsodeoxycholic AcidGastroenterologyAlanine TransaminaseMiddle Agedmedicine.diseaseLipidsUrsodeoxycholic acidClinical trialDose–response relationshipTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemalebusinessmedicine.drugThe lancet. Gastroenterologyhepatology
researchProduct

Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

2012

Background & Aims Microparticles released into the bloodstream upon activation or apoptosis of CD4+ and CD8+ T cells correlate with inflammation as determined by histologic analysis in patients with chronic hepatitis C (CHC). Patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) can be differentiated from those with CHC based on activation of distinct sets of immune cells in the liver. Methods We compared profiles of circulating microparticles from patients with NAFL and NASH (n = 67) to those of CHC (n = 42), with healthy individuals (controls) using flow cytometry; the profiles were correlated with inflammation grade and fibrosis stage based on histologic an…

AdultCD4-Positive T-LymphocytesLiver CirrhosisMaleLymphocyteBiologyCD8-Positive T-LymphocytesChronic liver diseaseSeverity of Illness IndexArticleCell-Derived MicroparticlesDiagnosis DifferentialImmune systemFibrosisCell-Derived MicroparticlesNon-alcoholic Fatty Liver DiseasemedicineHumansAgedAged 80 and overInflammationHepatologyFatty liverBiopsy NeedleGastroenterologyAlanine TransaminaseHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFlow CytometryFatty Livermedicine.anatomical_structureAlanine transaminaseLiverROC CurveCase-Control StudiesImmunologybiology.proteinLinear ModelsFemaleBiomarkersGastroenterology
researchProduct

Identification of CD4 T-Cell Epitopes in Soluble Liver Antigen/Liver Pancreas Autoantigen in Autoimmune Hepatitis

2008

Background & Aims Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease associated with autoantibodies and liver-infiltrating lymphocytes. Although autoantibodies are tested routinely to diagnose and classify AIH, liver-infiltrating lymphocytes are regarded as the primary factor for disease pathogenesis. The purpose of this study was to identify and characterize autoantigenic peptides within human AIH-specific soluble liver antigen/liver pancreas antigen (SLA/LP) that are targeted by CD4 + T cells and restricted by the disease susceptibility gene HLA-DRB1*0301. Methods HLA-DRB1*0301 transgenic mice were immunized with SLA/LP. Antibody and T-cell responses were analyzed with SLA…

AdultCD4-Positive T-LymphocytesMaleEpitopes T-LymphocyteMice TransgenicAutoimmune hepatitisBiologyAutoantigensPeripheral blood mononuclear cellArticleEpitopeImmunoenzyme TechniquesMiceYoung AdultLiver diseaseimmune system diseasesmedicineAnimalsHumansAgedAutoantibodiesHepatologymedicine.diagnostic_testELISPOTGastroenterologyAutoantibodyMiddle Agedmedicine.diseaseVirologyMice Inbred C57BLDisease Models AnimalHepatitis AutoimmuneImmunoassayImmunologybiology.proteinFemaleAntibodyGastroenterology
researchProduct

Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease

2015

Background/Aims We assessed whether obstructive sleep apnea (OSA) and nocturnal hypoxemia are associated with severity of liver fibrosis and carotid atherosclerosis in patients with biopsy-proven NAFLD and low prevalence of morbid obesity. Secondary aim was to explore the association of OSA and hypoxemia with NASH and severity of liver pathological changes. Methods Consecutive patients (n = 126) with chronically elevated ALT and NAFLD underwent STOP-BANG questionnaire to estimate OSA risk and ultrasonographic carotid assessment. In patients accepting to perform cardiorespiratory polygraphy (PG, n = 50), OSA was defined as an apnea/hypopnea index ≥5. A carotid atherosclerotic plaque was defi…

AdultCarotid Artery DiseasesLiver CirrhosisMalemedicine.medical_specialtyBiopsylcsh:MedicinePolysomnographySeverity of Illness IndexGastroenterologyLiver Function TestsNon-alcoholic Fatty Liver DiseaseRisk FactorsSurveys and QuestionnairesInternal medicineSeverity of illnessPrevalencemedicineHumansHypoxialcsh:ScienceAgedNAFLD OSAS ATHEROSCLEROSISSleep Apnea ObstructiveMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RFatty liverApneaSleep apneaMiddle AgedAtherosclerosismedicine.diseasePlaque Atheroscleroticrespiratory tract diseases3. Good healthObstructive sleep apneaEndocrinologyFemalelcsh:Qmedicine.symptombusinessLiver function testsHypopneaResearch ArticlePLOS ONE
researchProduct

Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection

1991

Hepatitis B virus deoxyribonucleic acid (HBV-DNA) was studied by Southern blot analysis in liver biopsy specimens from 75 HBsAg-positive patients with chronic liver disease living in southern Italy. Twenty-seven of the patients were hepatitis delta virus (HDV) superinfected. Intrahepatic HBV-DNA was detected in 54 (72%) patients, 32 (59%) of them with replicative forms. The presence of replicative forms was directly related to liver HBcAg and inversely related to liver HDAg, as shown by multivariate analysis. However, 14 patients with intrahepatic HBV-DNA non-replicative pattern and about half of HDV-infected patients were liver HBcAg and/or serum HBV-DNA positive, mostly in low amounts. Hi…

AdultDNA ReplicationMaleHepatitis B virusAdolescentvirusesPopulationVirus ReplicationChronic liver diseasemedicine.disease_causeVirusmedicineHumansChildeducationAgedHepatitis B viruseducation.field_of_studyHepatitis B Surface AntigensHepatologymedicine.diagnostic_testbiologyLiver Diseasesvirus diseasesMiddle Agedbiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseaseVirologyHepatitis Ddigestive system diseasesBlotting SouthernHBcAgLiverHepadnaviridaeChild PreschoolLiver biopsySuperinfectionChronic DiseaseDNA ViralImmunologyHepatitis Delta VirusJournal of Hepatology
researchProduct

Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis.

2008

We tested the hypothesis that the presence of bacterial DNA (bactDNA) in ascitic fluid and serum is associated with decreased survival in patients with cirrhosis. In a prospective, multicenter study, we analyzed the clinical evolution of 156 patients with cirrhosis and ascites (first or recurrence) with lower than 250 polymorphonuclear cells (PMN)/L, negative ascites bacteriological culture, and absence of other bacterial infections being admitted for evaluation of largevolume paracentesis, according to the presence of bactDNA at admission. Survival, causes of death, and successive hospital admissions were determined during a 12-month follow-up period. BactDNA was detected in 48 patients. T…

AdultDNA BacterialLiver CirrhosisMalemedicine.medical_specialtyCirrhosisNeutrophilsKaplan-Meier EstimatePeritonitisGastroenterologyLiver diseaseSpontaneous bacterial peritonitisRisk FactorsInternal medicineAscitesParacentesisEscherichia coliMedicineAscitic FluidHumansProspective StudiesProspective cohort studyCause of deathAgedAged 80 and overHepatologymedicine.diagnostic_testbusiness.industryIncidenceAscitesHepatologyMiddle Agedmedicine.diseasePrognosisSurgeryMultivariate AnalysisFemalemedicine.symptombusinessLiver FailureFollow-Up StudiesHepatology (Baltimore, Md.)
researchProduct

Vitamin B12 and hepatic enzyme serum levels correlate in male alcohol-dependent patients.

2001

- Vitamin B12 serum levels and markers for alcohol consumption were determined in 80 male alcohol-dependent patients. Spearman correlation coefficients (r(S)) were calculated. Significant positive correlations between vitamin B12 and hepatic enzyme values were found (gamma-glutamyltransferase: r(S) = 0.58; alanine aminotransferase: r(S) = 0.43; aspartate aminotransferase: r(S) = 0.47; glutamate dehydrogenase: r(S) = 0.43; all P:0.001). Therefore, for a proper interpretation of vitamin B12 levels, it may be clinically relevant to take markers of hepatocellular damage into account.

AdultErythrocyte IndicesMalemedicine.medical_specialtyCarbohydrate deficient transferrinAspartate transaminaseStatistics NonparametricGlutamate DehydrogenaseInternal medicineBlood plasmamedicineHumansCyanocobalaminVitamin B12Aspartate AminotransferasesLiver Diseases AlcoholicRetrospective StudiesbiologyGlutamate dehydrogenaseTransferrinnutritional and metabolic diseasesAlanine TransaminaseGeneral Medicinegamma-GlutamyltransferaseMiddle AgedAlcoholismVitamin B 12EndocrinologyAlanine transaminaseLiverToxicitybiology.proteinBiomarkersAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

Gadoxetic acid-enhanced MRI of transient hepatic enhancement differences: Another cause of hypointense observation on hepatobiliary phase

2018

Purpose: To retrospectively determine the frequency, natural history and factors associated with the presence of transient hepatic enhancement difference showing hypointensity on hepatobiliary phase images of gadoxetic acid-enhanced MRI. Materials and methods: Gadoxetic acid-enhanced MRI of 125 patients (91 men; 34 women) with transient hepatic enhancement difference were retrospectively reviewed. Three readers qualitatively and quantitatively evaluated MR imaging features and evolution at follow up. The Chi-square test, Fisher's exact test and Kruskall-Wallis rank test were used for statistical analysis. Results: Transient hepatic enhancement difference were hypointense on hepatobiliary ph…

AdultGadolinium DTPAMaleGadoxetic acidGadoxetic acidContrast MediaAbdomen/GI030218 nuclear medicine & medical imagingHemodynamics/flow dynamic03 medical and health sciences0302 clinical medicineImage Processing Computer-AssistedHumansMedicineRadiology Nuclear Medicine and imagingStatistical analysisAgedRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryLiver DiseasesGeneral MedicineMiddle AgedImage EnhancementMagnetic Resonance ImagingMr imagingHyperintensityMR-imagingExact testLiver030220 oncology & carcinogenesisMultivariate AnalysisHepatocytesHepatobiliary phaseFemalebusinessNuclear medicinemedicine.drugEuropean Journal of Radiology
researchProduct

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver

2017

Abstract Background and Aims Nonalcoholic fatty liver disease is epidemiologically associated with hepatic and metabolic disorders. The aim of this study was to examine whether hepatic fat accumulation has a causal role in determining liver damage and insulin resistance. Methods We performed a Mendelian randomization analysis using risk alleles in PNPLA3, TM6SF2, GCKR and MBOAT7, and a polygenic risk score for hepatic fat, as instruments. We evaluated complementary cohorts of at‐risk individuals and individuals from the general population: 1515 from the liver biopsy cohort (LBC), 3329 from the Swedish Obese Subjects Study (SOS) and 4570 from the population‐based Dallas Heart Study (DHS). Re…

AdultGenetic MarkersLiver CirrhosisMalenonalcoholic fatty liver diseaseNon-alcoholic Fatty Liver Diseaseinsulin resistanceHumansgeneticsProspective StudiesAdaptor Proteins Signal TransducingSettore MED/12 - GastroenterologiafibrosisMembrane ProteinsOriginal ArticlesLipaseMendelian Randomization AnalysisAdipose TissueDiabetes Mellitus Type 2Chronic Diseasemendelian randomizationOriginal ArticleFemaletype 2 diabetesgeneticfibrosiAcyltransferases
researchProduct